2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Workforce, Adverse Events, Clinical Practice (Health Services and Quality), Health Economics, Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Bleeding and Clotting, Hemophilia, Thromboembolism, Thrombotic Disorders, Bone Marrow Failure Syndromes, Paroxysmal Nocturnal Hemoglobinuria, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Metabolic Disorders, Iron Deficiency, Iron Overload, B Cell Lymphoma, Research, Clinical Research, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4386 More testing, less clarity: Interpretability and management-changing yield of thrombophilia testing after acute ischemic stroke

Tro Sekayan, MD, Grace Harrington2, Chanika Assavarittirong, MD3
1 University of California, San Diego, San Diego, California, United States
2 University of California, San Diego, San Diego, California, United States
3 University of California, San Diego, San Diego, California, United States

Background:
The association of inherited thrombophilia with arterial thrombosis is weak, and routine testing after acute ischemic stroke is not guideline-supported. Furthermore, functional thrombophilia assays are difficult to interpret during the acute phase. Antiphospholipid syndrome (APS) is an acquired thrombophilia associated with arterial thrombosis, but diagnosis requires persistent antiphospholipid antibody (aPL) positivity at least 12 weeks apart. As the baseline phase of a quality-improvement initiative, we evaluated inpatient thrombophilia testing patterns, interpretability, diagnostic yield, and impact on antithrombotic management.

Methods:
We conducted a retrospective, single-center cohort study of adults hospitalized at the University of California San Diego with ischemic stroke from 2020 to 2025 who underwent thrombophilia testing. Patients with hemorrhagic stroke, cerebral venous sinus thrombosis, known atrial fibrillation (AF), or preexisting anticoagulation use were excluded. Stroke etiology documented as cryptogenic, embolic stroke of undetermined source, or undetermined was classified as cryptogenic. Abnormal functional assays obtained during acute hospitalization were classified as uninterpretable, and aPL positivity without repeat confirmation after at least 12 weeks was classified as unconfirmed. A strict management-changing result required documented initiation of anticoagulation, with or without concomitant antiplatelet therapy, explicit attribution of this change to the thrombophilia result, and absence of another indication for anticoagulation.

Results: Among 2,549 patients with ischemic stroke, 415 underwent thrombophilia testing and 341 met eligibility criteria. Median age was 56 years (range, 19–93), 58% were male, 32% were aged <50 years. Cryptogenic stroke was diagnosed in 48% at discharge. Overall, 47% were White, 22% Hispanic, 13% African American, 8% Asian, and 10% other/unknown.

Broad testing, defined as inherited thrombophilia, APS, and other lower-yield testing (FVIII, MTHFR genotyping, homocysteine, other factor assays) was performed in 96%; only 4% received APS-focused testing. At least 1 abnormal result occurred in 88% of patients, and 61% had at least 1 uninterpretable result.

The inherited thrombophilia panel comprised 1,527 assays. All 133 abnormal protein C activity, protein S free antigen, or antithrombin functional assay results were classified as uninterpretable. Factor V Leiden and prothrombin G20210A testing identified 10 and 12 heterozygous variants, respectively, among 21 patients, including 1 double heterozygote. MTHFR genotyping was performed in 90% of patients; 81% of those carried a polymorphism, of whom 77% had normal serum homocysteine levels. Inherited thrombophilia and MTHFR testing produced no attributable management change.

Only 24% received all 5 prespecified APS tests: lupus anticoagulant, anticardiolipin IgG and IgM, and anti-beta2-glycoprotein I IgG and IgM. Incomplete testing was largely attributable to low anticardiolipin IgM testing. At least 1 aPL was initially positive in 71 patients, but only 20/71 aPL-positive patients (28%) underwent repeat testing. Confirmatory testing occurred in 18/31 aPL-positive patients (58%) with hematology involvement compared with 2/40 (5%) without hematology involvement, an absolute difference of 53 percentage points.

Any management change occurred in 29%, including anticoagulation initiation in 27%. Most changes reflected competing indications, most commonly concurrent venous thromboembolism or newly diagnosed AF. Under the broader adjudication, 3.8% were classified as having a strict management-changing result.

Conclusions:
Broad inpatient thrombophilia testing after ischemic stroke generated frequent abnormal and uninterpretable findings but rarely produced an independently attributable change in management. Inherited thrombophilia and MTHFR testing did not contribute to any strict management-changing result. Hematology involvement was associated with higher completion of confirmatory APS testing. These findings support the implementation of electronic order-set safeguards for a selective, complete APS-testing pathway with standardized hematology follow-up if positive, and the reservation of selected additional testing for the outpatient setting. Future evaluation should assess whether this approach reduces unnecessary testing costs, false-positive results, and overall healthcare burden.
Grace Harrington: No relevant conflicts of interest to declare.